SUVPF:OTC-Sartorius Aktiengesellschaft (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 198.8499

Change

0.00 (0.00)%

Market Cap

USD 16.40B

Volume

N/A

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Sartorius Aktiengesellschaft provides bioprocess solutions, and lab products and services worldwide. The company offers multi-parallel, benchtop, single-use, stainless steel, cell culture, rocking motion, and microbial bioreactors; software apps for bioreactors and cell culture shake flasks; fermenters; cell culture media, biolayer interferometry, microbiological testing, and fluid management products; buffers; reagents; plasmids; cellcelector flexs, incubator flowboxes, nanowell arrays, and capillaries and tips; high-throughput screening by cytometry; ultrafiltration solutions; syringe, membrane, glass and quartz microfiber, clarification, syringeless, and in-line filters; and lab chromatography, and filters and blotting papers. It also provides live-cell analysis systems, reagents and consumables, and support and services; live-cell imaging and analysis software; contract manufacturing and integration; OEM membranes and devices, weigh cells, and data analytics; connectivity, and pipetting and dispensing products; electronic and mechanical pipettes, pipette tips, bottle-top dispensers, and pipette controllers and accessories; process automation platform and software, sensors and analyzers, biomolecule analysis tools, and data analytics software; chromatography consumables, columns, and systems; and surface plasmon resonance and process filtration products. The company offers water purification systems; lab data and fleet management software; lab balances, pipette calibration, mass comparators and metrology, moisture analyzers, weights and weight sets, paint mixing solutions, and weighing accessories; and bioprocess consulting and engineering, biologics testing, cell culture media, instrument, octet service and support, and validation services. It serves the life science research, biopharmaceutical manufacturing, cell and gene therapy, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-05-14 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ESLOY Essilor International SA

-1.96 (-1.38%)

USD 126.80B
ESLOF EssilorLuxottica Société ano..

-5.21 (-1.81%)

USD 125.52B
HOCPF HOYA Corporation

N/A

USD 43.54B
HOCPY Hoya Corp

-3.40 (-2.74%)

USD 41.79B
CLPBY Coloplast A

+0.06 (+0.67%)

USD 30.06B
TRUMF Terumo Corporation

-0.11 (-0.64%)

USD 28.03B
SRTOY Sartorius Stedim Biotech S.A

N/A

USD 21.84B
CLPBF Coloplast A/S

N/A

USD 21.70B
SAUHF Straumann Holding AG

-4.96 (-3.58%)

USD 20.49B
SDMHF Sartorius Stedim Biotech S.A

N/A

USD 19.85B

ETFs Containing SUVPF

C007:XETRA Amundi Index Solutions - .. 0.00 % 0.00 %

-0.46 (-0.83%)

USD 0.16B
E907:XETRA Lyxor 1 MDAX (DR) UCITS E.. 0.00 % 0.00 %

-1.20 (-0.83%)

USD 0.13B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -9.55% 29% F 32% F
Dividend Return 0.36% 29% F 5% F
Total Return -9.18% 30% F 31% F
Trailing 12 Months  
Capital Gain -38.25% 20% F 27% F
Dividend Return 0.25% 12% F 2% F
Total Return -38.00% 20% F 26% F
Trailing 5 Years  
Capital Gain -38.82% 39% F 39% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.82% 37% F 37% F
Average Annual (5 Year Horizon)  
Capital Gain -8.37% 31% F 28% F
Dividend Return -8.23% 31% F 26% F
Total Return 0.14% 8% B- 7% C-
Risk Return Profile  
Volatility (Standard Deviation) 32.41% 71% C- 67% D+
Risk Adjusted Return -25.39% 29% F 25% F
Market Capitalization 16.40B 80% B- 93% A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector